These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 408002)

  • 1. On determining the levels of treatment to optimize the probability of a favorable response.
    Carter WH; Wampler GL; Crews SL; Howells R
    Cancer Treat Rep; 1977 Aug; 61(5):849-53. PubMed ID: 408002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival analysis of drug combinations using a hazards model with time-dependent covariates.
    Stablein DM; Carter WH; Wampler GL
    Biometrics; 1980 Sep; 36(3):537-46. PubMed ID: 6783143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An improved method for analyzing survival data from combination chemotherapy experiments.
    Carter WH; Stablein DM; Wampler GL
    Cancer Res; 1979 Sep; 39(9):3446-53. PubMed ID: 476674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.
    Wampler GL; Carter WH; Campbell ED; Goldman ID
    Cancer Treat Rep; 1987 Jun; 71(6):581-91. PubMed ID: 3581096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICRF-187 in clinical oncology.
    Poster DS; Penta JS; Bruno S; Macdonald JS
    Cancer Clin Trials; 1981; 4(2):143-6. PubMed ID: 6788388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy: arriving at optimal treatment levels by incorporating side effect constraints.
    Wampler GL; Carter WH; Williams VR
    Cancer Treat Rep; 1978 Mar; 62(3):333-40. PubMed ID: 647694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical designs for experiments in combination therapy.
    Miller I
    Cancer Chemother Rep 2; 1974 Mar; 4(1):151-6. PubMed ID: 4826494
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug activity and therapeutic synergism in cancer treatment.
    Carter WH; Wampler GL; Stablein DM; Campbell ED
    Cancer Res; 1982 Aug; 42(8):2963-71. PubMed ID: 6807534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A method for determining schedule dependency in tissue culture.
    Wampler GL; Carter WH; Campbell ED; Keefe PA
    J Biopharm Stat; 1991; 1(2):261-86. PubMed ID: 1668959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors.
    Lake LM; Grunden EE; Johnson BM
    Cancer Res; 1975 Oct; 35(10):2858-63. PubMed ID: 808270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A methodological approach to the prediction of anticancer drug effect in humans.
    Durkin WJ; Ghanta VK; Balch CM; Davis DW; Hiramoto RN
    Cancer Res; 1979 Feb; 39(2 Pt 1):402-7. PubMed ID: 761212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D; Hilliard SL
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract]   [Full Text] [Related]  

  • 14. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in the diabetogenic effect of alloxan in mice by treatment with the antineoplastic agent ICRF-187.
    El-Hage AN; Herman EH; Ferrans VJ
    Res Commun Chem Pathol Pharmacol; 1981 Sep; 33(3):509-23. PubMed ID: 7036302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single versus combination chemotherapy of L1210 leukemia.
    Koza I; Balázová E; Ujházy V
    Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental approach for the search of effective drug combination in cancer chemotherapy.
    Bello JL; Kariev NI; Mainardi JV; Betancourt M; Lage A; Barroso MC; Alfonso L
    Neoplasma; 1982; 29(1):65-71. PubMed ID: 7070556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of AT1727 on growth and metastasis of murine tumours.
    Li XT; Hutchinson GE; Pym BA; Finch M; Hellmann K
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):283-7. PubMed ID: 6681774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.